1 / 5

Prevention of Recurrent Venous Thromboembolism

PREVENT (Warfarin) Trial. Prevention of Recurrent Venous Thromboembolism. N Engl J Med Apr 10 2003;348(15) :1425-1434. PREVENT Trial. 508 patients with documented idiopathic venous thromboembolism, > 3 uninterrupted months of oral anticoagulation therapy with full-dose warfarin

martine
Download Presentation

Prevention of Recurrent Venous Thromboembolism

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PREVENT (Warfarin) Trial Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr 10 2003;348(15) :1425-1434

  2. PREVENT Trial • 508 patients with documented idiopathic venous thromboembolism, >3 uninterrupted months of oral anticoagulation therapy with full-dose warfarin • Age >30 years • Open-label therapy for 28 days • To determine if warfarin dose could be titrated to an INR of 1.5 to 2.0 without exceeding 10 mg per day • To see if patients could maintain a compliance of 85% Warfarin (target INR, 1.5-2.0) (n = 255) Placebo (n = 253) • Endpoints (mean follow-up 2.1 years): • Primary – 1) recurrent venous thromboembolism and 2) composite of recurrent venous thromboembolism, major hemorrhage, or death N Engl J Med Apr 10 2003;348(15) :1425-1434

  3. PREVENT Trial: Composite Endpoint Composite Endpoint* HR = 0.52, p=0.01 Trial discontinued early by the DSMB, due to a large, significant benefit with low-intensity warfarin therapy and the absence of any substantial evidence of any significant untoward side effects * Composite of recurrent thromboembolism, major bleed and death Placebo Warfarin N Engl J Med Apr 10 2003;348(15) :1425-1434

  4. PREVENT Trial All-Cause Mortality HR = 0.50, p=0.26 Recurrent Venous Thromboembolism HR = 0.36, p<0.001 Placebo Warfarin Warfarin Placebo N Engl J Med Apr 10 2003;348(15) :1425-1434

  5. PREVENT: Conclusions • Among patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for six months, treatment with low-intensity warfarin (target INR, 1.5-2.0) was associated with a reduction in recurrent venous thromboembolism and in the composite of recurrent venous thromboembolism, major hemorrhage, or death during follow-up • No significant excess major bleeding occurred in the warfarin arm • First randomized trial to examine the use of low-intensity warfarin therapy, rather than full-dose therapy in this population

More Related